A medical marketplace can easily ask too much. Weight, diagnosis, symptoms, medication history, and insurance identifiers might make a quiz feel personalized, but they also turn a simple directory interaction into collection of sensitive health information.
The GLP.directory matcher does something smaller. It asks four access questions—what job the reader is doing, how they prefer to pay, which advertised medication route to prioritize, and what support structure matters. It then reorders public profiles using those declared preferences.
The score is intentionally legible
A matching journey adds four points. Payment and medication route matches add three each. Support adds two. Ties preserve the editorial catalog order, which is based on completeness for the launch view rather than a claim of clinical superiority.
No health outcome is predicted. No program is called medically suitable. State availability, clinician approval, pharmacy fulfillment, insurance coverage, and price remain facts to confirm directly.
Money stays outside the ranking
The scoring code receives no affiliate-status or payout field. Commercial destinations are stored separately, and a profile displays a commission note only after a relationship is active. The FTC’s disclosure guidance is the minimum; the more important safeguard is that payment cannot change the score.
The first version has limits
The launch catalog uses broad “US multi-state; confirm at intake” labels because program-by-program state matrices require frequent verification. Many prices are marked “confirm live terms” where public pages mix paths or reveal terms after a quiz. Infrastructure relationships are only named when an official source names them.
These omissions are visible by design. A useful evidence product should distinguish “not found” from “no,” and “company says” from “independently verified.” The next data layer will add structured state, pharmacy, and first-year-cost fields only as the sourcing supports them.
A worked scoring example
Suppose a reader selects switching, insurance support, no medication-route preference, and clinician access. A profile tagged for switching receives four points; insurance receives three; either route changes nothing; and clinician access receives two. A profile matching all relevant preferences scores nine. A tie keeps the underlying editorial order. The score is a sorting aid, not a rating of care quality.
Missing evidence does not become a negative claim
“Not publicly confirmed” is not the same as “the provider does not offer it.” The first means our reviewed sources did not support a precise answer. A future version may reduce confidence when important fields are stale or absent, but it should not invent a no. Every change to scoring belongs in the public methodology and version notes.
What enters the score
Privacy is part of product quality
A directory does not need symptoms, diagnosis, body measurements, insurance identifiers, or medication history to sort public research by access preference. Keeping those questions out lowers the consequence of a simple browsing interaction. Clinical history should go only to the care practice through a channel it authorizes.
How to challenge a result
Readers and providers can compare the result with the profile fields and submit a documented correction. Commercial pressure, backlink offers, and affiliate economics do not change the record. See the full matcher methodology, browse the source-dated provider catalog, or use side-by-side comparison after the shortlist is generated.
Sources: GLP.directory matcher source code and methodology; FTC disclosure guidance. Version 0.1 reviewed September 10, 2026.
Source ledger
Primary and first-party sources
- Federal Trade Commissionftc.gov/business-guidance/resources/disclosures-101-social-media-influencers ↗
- developers.google.comdevelopers.google.com/search/docs/fundamentals/creating-helpful-content ↗
- hhs.govhhs.gov/hipaa/for-professionals/privacy/guidance/cell-phone-hipaa/index.html ↗
These links support specific facts; inclusion is not an endorsement. Terms can change after the review date.
This report is general information, not medical advice. A licensed clinician who knows your history should guide treatment, prescribing, dosing, and switching decisions. Compounded drugs are not FDA approved.